Biobanks Market – Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks, Others), By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell Lines, Others), By Application (Therapeutics, Drug Discovery, Clinical Diagnostics, Clinical Research), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others), By Region, and By Competition, 2020-2030F

Market Overview

The Global Biobanks Market, valued at USD 79.34 Billion in 2024, is projected to experience a CAGR of 8.98% to reach USD 132.91 Billion by 2030. Biobanks are organized repositories storing biological materials, such as blood and tissue, along with associated clinical and demographic data, primarily for research purposes. The global biobanks market growth is fundamentally driven by the increasing prevalence of chronic diseases, significant advancements in personalized medicine, and rising investments in biomedical research and drug discovery initiatives. According to BBMRI-ERIC, in 2023, the consortium connected approximately 400 biobanks and over 2600 collections across 32 countries, serving 9,000 users.

Despite this expansion, a significant challenge impeding market growth remains the substantial upfront capital expenditure required for establishing and maintaining modern biobanking facilities, encompassing specialized infrastructure, advanced equipment, and stringent regulatory compliance. This financial barrier can limit the entry of new entities and the expansion capabilities of existing smaller organizations.

Key Market Drivers

The increased demand for high-quality biospecimens in research represents a primary market driver, stemming from the critical need for reliable biological materials in scientific inquiry. The integrity and standardized processing of samples are crucial for producing reproducible research outcomes across diverse disciplines including oncology, neuroscience, and infectious diseases. This stringent demand compels biobanks to implement rigorous quality control measures and advanced storage protocols. According to a July 2024 arXiv article, "Quantifying the Impact of Biobanks and Cohort Studies", 2,663 unique biobanks were mentioned across 228,761 scientific articles as of October 2023, underscoring their critical role in research dissemination and impact. This extensive utilization demonstrates the sustained reliance of the scientific community on robust biospecimen repositories to advance medical understanding.

Advancements in genomics and various omics technologies profoundly influence the biobanks market, enabling researchers to explore molecular disease intricacies at unprecedented resolution. These sophisticated analytical tools necessitate a broader range and higher specificity of biospecimens. For instance, the National Human Genome Research Institute reported, as cited in a 2024 report on Single-cell Omics Market, that the cost of sequencing a human genome significantly decreased from $100 million in 2001 to under $1,000, thereby expanding access to advanced genomic analysis for researchers. This technological progress not only fuels demand but also attracts substantial external support. According to a July 2024 announcement by the UK Science and Technology Secretary, Amazon Web Services committed approximately £8 million in cloud computing credits to support the UK Biobank's data infrastructure, highlighting significant industry contributions.

Download Free Sample Report

Key Market Challenges

The substantial upfront capital expenditure required for establishing and maintaining modern biobanking facilities presents a significant challenging factor. This financial barrier directly impedes the expansion of the global biobanks market by limiting the entry of new organizations and restricting the growth capabilities of smaller existing entities. Establishing a biobank necessitates considerable investment in specialized infrastructure, advanced equipment for sample processing and long-term storage, and ongoing expenditure for stringent regulatory compliance and highly skilled personnel. The cumulative financial commitment for such operations is substantial. For instance, according to the International Society for Biological and Environmental Repositories (ISBER), its total expenses in 2024 reached $1,461,396, reflecting the significant financial ecosystem required to support the global biobanking community. This high initial outlay and continuous operational funding create an insurmountable hurdle for many potential market participants, thereby slowing the overall rate of market development and consolidation. The necessity for sustained financial resources for both establishment and long-term viability means that only well-funded organizations can realistically enter or significantly scale up their operations.

Key Market Trends

The Global Biobanks Market is significantly shaped by the increasing prevalence of cord blood and stem cell banking. This trend is driven by growing awareness of stem cells' therapeutic potential across various medical conditions, including hematological disorders and certain cancers. The World Marrow Donor Association (WMDA) reported a substantial inventory of 760,832 cord blood units as of July 2024, demonstrating the scale of these specialized biobanking efforts. This growth is further supported by an expanding number of medical applications and ongoing research into regenerative medicine. For instance, according to a June 2024 publication titled 'Optimizing Umbilical Cord Blood Units for Rapid Shipment,' one institution alone managed an inventory exceeding 60,000 cryopreserved cord blood units, highlighting the significant individual contributions to this expanding resource.

Concurrently, the emergence of global biobank data harmonization initiatives is profoundly influencing the market by fostering interoperability and collaborative research. These initiatives aim to establish common standards and frameworks to facilitate the efficient sharing and analysis of vast and diverse biological data across different repositories. This collaborative environment is supported by extensive networks, as more than 500 leading organizations in healthcare, research, and technology actively participate in the Global Alliance for Genomics and Health (GA4GH) community, contributing to the development of these shared standards. A notable example of this trend is the Cancer Research Data Commons (CRDC) which marked five years as a Driver Project with the Global Alliance for Genomics and Health (GA4GH) in 2025, having integrated GA4GH's Data Repository Service (DRS) and Passports specifications into its infrastructure to enhance data accessibility and secure exchange for research purposes.

Segmental Insights

Disease-Oriented Biobanks emerge as the fastest-growing segment within the Global Biobanks Market, primarily propelled by the increasing global prevalence of chronic and complex diseases. This growth is intrinsically linked to the escalating demand for highly specific biospecimens that are indispensable for advancing precision medicine initiatives, including the identification of disease biomarkers and the creation of tailored therapeutic strategies. Furthermore, these specialized biobanks serve as critical infrastructure, significantly supporting pharmaceutical and biotechnology companies in accelerating targeted drug discovery and development efforts. The segment's expansion is also reinforced by the ongoing need for robust ethical and regulatory frameworks, which ensure the responsible collection, storage, and utilization of biological samples for research, thereby fostering trust and scientific progress.

Regional Insights

North America stands as a leading region in the Global Biobanks Market, primarily due to its robust pharmaceutical and biotechnology industries. This market leadership is further solidified by substantial government and private sector funding dedicated to extensive biomedical research, genomics, and precision medicine initiatives. The region benefits from an advanced healthcare infrastructure and a high concentration of academic institutions actively engaged in cutting-edge research. Furthermore, a well-established regulatory framework supports efficient biobanking practices, ensuring quality and compliance essential for the continuous demand for biospecimens in drug discovery and development.

Recent Developments

• In January 2025, UK Biobank launched the world's largest protein study, funded by a consortium of 14 leading biopharmaceutical companies, known as the UK Biobank Pharma Proteomics Project. This groundbreaking research endeavors to measure up to 5,400 proteins across 600,000 samples, including initial and follow-up samples from half a million participants. The project aims to create a unique database detailing how changes in protein levels over time influence disease development. This initiative will enable researchers to simultaneously examine proteomic and genetic data from a large cohort, accelerating the discovery of diagnostic and prognostic markers, thereby significantly impacting medical breakthroughs within the global biobanks market.

• In August 2024, the Finnish Biobank Cooperative (FINBB) entered a strategic partnership with Owkin, an AI-driven biotech startup, to advance AI integration in medical research. This collaboration focused on leveraging extensive biobank data to develop innovative solutions for drug discovery and development. The partnership granted access to 11 million biobank samples and biodata from all public biobanks in Finland, utilizing FINBB's Fingenious® service. Their initial research project concentrated on inflammatory bowel disease, aiming to streamline biobank data use to accelerate the development of targeted treatments, thereby enriching biobank collections and benefiting patients.

• In April 2024, UK Biobank’s ongoing collaboration with DNAnexus was recognized with the Bio-IT World 2024 Innovative Best Practices Global Impact Award. DNAnexus, a provider of the Precision Health Data Cloud, supported the development of the cloud-based UK Biobank Research Analysis Platform. This platform enables approved researchers worldwide to access and analyze UK Biobank’s extensive database, including whole-genome sequencing data from 500,000 participants. This partnership facilitates global scientific discovery by providing tools and computing power for analyzing vast de-identified health and lifestyle data, driving the identification of new diagnostics and treatments within the global biobanks market.

• In March 2024, Galatea Bio secured $25 million in funding to expand its global biobank, aiming to diversify genomic research. The company's initiative focused on enhancing high-throughput sequencing and AI-driven genomic analysis. This expansion targets underrepresented populations, significantly scaling its efforts to sequence 10 million participants, with a priority on non-European ancestries. The collected data, combined with longitudinal health information, is intended to improve disease modeling and accelerate discoveries. This investment directly contributes to the growth and capabilities of the global biobanks market by increasing the diversity and volume of available genomic data for research.

Key Market Players

• Danaher Corporation
• Merck KgaA
• Becton, Dickinson, and Company
• Avantor, Inc.
• Thermo Fisher Scientific, Inc
• Tecan Trading AG
• QIAGEN N.V.
• Hamilton Company
• ProMedDx, LLC
• ISENET Biobanking S.r.l

Report Scope:

In this report, the Global Biobanks Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Biobanks Market, By Type:

o   Disease Oriented Biobanks

o   Population Based Biobanks

o   Tissue Biobanks

o   Others

• Biobanks Market, By Sample Type:

o   Blood Products

o   Biological Fluids

o   Nucleic Acid

o   Cell Lines

o   Others

• Biobanks Market, By Application:

o   Therapeutics

o   Drug Discovery

o   Clinical Diagnostics

o   Clinical Research

• Biobanks Market, By End User:

o   Academic & Research Institutes

o   Pharmaceutical & Biotechnology Companies

o   Hospitals & Clinics

o   Others

• Biobanks Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biobanks Market.

Available Customizations:

Global Biobanks Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Biobanks Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]